47 results on '"Boers, M."'
Search Results
2. Calibration of the Dutch-Flemish PROMIS Pain Behavior item bank in patients with chronic pain
3. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases
4. Subclinical renal dysfunction is independently associated with cardiovascular events in rheumatoid arthritis: the CARRÉ Study
5. Impact of different descriptions of the Kellgren and Lawrence classification criteria on the diagnosis of knee osteoarthritis
6. Prevalence of cardiovascular diseases in psoriatic arthritis resembles that of rheumatoid arthritis
7. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice
8. Circulating microparticles remain associated with complement activation despite intensive anti-inflammatory therapy in early rheumatoid arthritis
9. Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases
10. Effect of dexamethasone on autoantibody levels and arthritis development in patients with arthralgia: a randomised trial
11. Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study
12. The time has come to limit the placebo period in rheumatoid arthritis trials to 3 months: a systematic comparison of 3- and 6-month response rates in trials of biological agents
13. IgM-rheumatoid factor and anti-cyclic citrullinated peptide decrease by 50% during intensive treatment in early rheumatoid arthritis
14. High incidence of cardiovascular events in patients with rheumatoid arthritis
15. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRÉ Investigation
16. CHECK (Cohort Hip and Cohort Knee): similarities and differences with the Osteoarthritis Initiative
17. Inclusion of glucocorticoids in recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: comment on the article by Saag et al
18. Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial
19. Reporting Disease Activity in Clinical Trials of Patients With Rheumatoid Arthritis: EULAR/ACR Collaborative Recommendations
20. Discordant perspectives of rheumatologists and patients on COBRA combination therapy in rheumatoid arthritis
21. Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients with rheumatoid arthritis
22. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations
23. Differences in descriptions of Kellgren and Lawrence grades of knee osteoarthritis
24. A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout
25. Decreasing incidence of symptomatic gastrointestinal ulcers and ulcer complications in patients with rheumatoid arthritis
26. Hexokinase III, cyclin A and galectin-3 are overexpressed in malignant follicular thyroid nodules
27. COBRA combination therapy in daily practice—getting back to the future
28. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases
29. Consensus Dutch Health Assessment Questionnaire
30. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction
31. Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission
32. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data
33. Arthritis instantaneously causes collagen type I and type II degradation in patients with early rheumatoid arthritis: a longitudinal analysis
34. Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results
35. Rapid detection of parainfluenza virus in respiratory samples: a 3-year experience: P1629
36. Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change
37. Low dose prednisolone for treatment of RA
38. Glucocorticoids in the treatment of early and late RA
39. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis
40. How to interpret radiological progression in randomized clinical trials?
41. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology
42. Rheumatoid factor measured by fluoroimmunoassay: a responsive measure of rheumatoid arthritis disease activity that is associated with joint damage
43. Reproducibility and clinical value of 18F-fluorodeoxyglucose positron emission tomography in recurrent melanoma
44. Early and Aggressive Treatment of Rheumatoid Arthritis Patients Affects the Association of HLA Class II Antigens with Progression of Joint Damage
45. Bone turnover, joint damage and bone mineral density in early rheumatoid arthritis treated with combination therapy including high-dose prednisolone
46. Responsiveness of the core set, response criteria, and utilities in early rheumatoid arthritis
47. CD8+ T cells and not CD4+ T cells are hyporesponsive to CD28- and CD40L-mediated activation in HIV-infected subjects
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.